CollPlant Biotechnologies, a regenerative and aesthetic medicine company developing technologies and products for tissue regeneration and organ manufacturing, announces the publication of a study in Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons.
titled “The Potential Use of Novel Plant-Derived Recombinant Human Collagen in Aesthetic Medicine,” the study highlights favorable in-vitro and in-vivo results of CollPlant’s photocurable dermal filler as well as other potential applications of this collagen technology in aesthetic medicine.
Following light illumination of the skin, CollPlant’s photocurable dermal filler showed improved physical properties compared with standard of care, suggesting enhanced lifting effect and appearance. Biological properties assessed in a preclinical animal model, showed that the photocurable filler enhances cell proliferation and new tissue regeneration compared to standard of care.
“We are very pleased with these promising results of CollPlant’s photocurable collagen technology, demonstrating its broad potential in aesthetic medicine applications. Regenerative medicine aims to mimic nature, providing cells with growing environment as similar as possible to the original one. These published results further demonstrate recombinant human collagen’s (rhCollagen) ability to serve as the ideal building block in regenerative medicine applications.”
— Yehiel Tal, CollPlant’s Chief Executive Officer
CollPlant’s photocurable dermal filler is composed of rhCollagen and hyaluronic acid and is intended for contour deficiencies corrections. The filler is designed to allow easy injection, followed by sculpting and in-situ hardening by light illumination of the skin.
[Source(s): CollPlant, PR Newswire]
